Melita Irving

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


60 publications

En préparation
 
DNA-Dependent Protein Kinase Inhibitors PI-103 and Samotolisib Augment CRISPR/Cas9 Knockin Efficiency in Human T Cells
Džafo Emina, Hafezi Morteza, Giordano Attianese Greta Maria Paola, Reichenbach Patrick, Grillet Stephane, Scholten Kirsten, Coukos George, Irving Melita, Gentner Bernhard.
[DOI][serval:BIB_7318185C7D2B]
 
Drug-controlled CAR-T cells through the regulation of cell-cell interactions
Scheller Leo, Attianese Greta Maria Paola Giordano, Castellanos-Rueda Rocio, Di Roberto Raphael B, Barden Markus, Riboulet Melanie, Shui Sailan, Cribioli Elisabetta, Marchand Anthony, Georgeon Sandrine et al..
[DOI][serval:BIB_186EB91D930B]
 
CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells
Ziegler Dorian V., Leal-Esteban Lucia, Parashar Kanishka, Castro Wilson, Zanou Nadège, Huber Katharina, López-Alcalá Jaime, Berney Xavier Pascal, Malagón María M, Roger Catherine et al..
[DOI][serval:BIB_20CA91209F3E]
2025
 
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer.
Ziegler D.V., Parashar K., Leal-Esteban L., López-Alcalá J., Castro W., Zanou N., Martinez-Carreres L., Huber K., Berney X.P., Malagón M.M. et al., 2025/01/09. Nature communications, 16 (1) p. 541. Peer-reviewed.
[DOI][Pmid][serval:BIB_C59FE7AA0BFC]
2024
 
Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.
Semilietof A., Stefanidis E., Gray-Gaillard E., Pujol J., D'Esposito A., Reichenbach P., Guillaume P., Zoete V., Irving M., Michielin O., 2024/12/22. Journal for immunotherapy of cancer, 12 (12). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E6A97A97468D]
Acidity suppresses CD8 + T-cell function by perturbing IL-2, mTORC1, and c-Myc signaling.
Vuillefroy de Silly R., Pericou L., Seijo B., Crespo I., Irving M., 2024/11. The EMBO journal, 43 (21) pp. 4922-4953. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D12C9C14E19B]
Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs.
Giordano Attianese GMP, Shui S., Cribioli E., Triboulet M., Scheller L., Hafezi M., Reichenbach P., Gainza P., Georgeon S., Correia B.E. et al., 2024/10/29. Proceedings of the National Academy of Sciences of the United States of America, 121 (44) pp. e2405085121. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D70C09408C95]
Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.
Martin S., Wendlinger L., Zitti B., Hicham M., Postupalenko V., Marx L., Giordano-Attianese G., Cribioli E., Irving M., Litvinenko A. et al., 2024/08/28. EJNMMI research, 14 (1) p. 77. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F843327A454B]
Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
Stefanidis E., Semilietof A., Pujol J., Seijo B., Scholten K., Zoete V., Michielin O., Sandaltzopoulos R., Coukos G., Irving M., 2024/04/23. The Journal of clinical investigation, 134 (11). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_36EE50DF7CA8]
2023
Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP, Ash S., Irving M., 2023/11. Immunological reviews, 320 (1) pp. 166-198. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_777D795B1683]
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
Tillé L., Cropp D., Charmoy M., Reichenbach P., Andreatta M., Wyss T., Bodley G., Crespo I., Nassiri S., Lourenco J. et al., 2023/10. Nature immunology, 24 (10) pp. 1645-1653. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B944FAF7B77]
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Reichenbach P., Giordano Attianese GMP, Ouchen K., Cribioli E., Triboulet M., Ash S., Saillard M., Vuillefroy de Silly R., Coukos G., Irving M., 2023/09. Nature biomedical engineering, 7 (9) pp. 1063-1080. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_22CADB5FE4EC]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
Corria-Osorio J., Carmona S.J., Stefanidis E., Andreatta M., Ortiz-Miranda Y., Muller T., Rota I.A., Crespo I., Seijo B., Castro W. et al., 2023/05. Nature immunology, 24 (5) pp. 869-883. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6529135A8DD]
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC23FF064822]
 
A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism.
Maric T., Bazhin A., Khodakivskyi P., Mikhaylov G., Solodnikova E., Yevtodiyenko A., Giordano Attianese GMP, Coukos G., Irving M., Joffraud M. et al., 2023/01/15. Biosensors & bioelectronics, 220 p. 114826. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C15EADDDA9C7]
2022
 
IL-2 engineered MSCs rescue T cells in tumours.
Irving M., Ortiz-Miranda Y., Coukos G., 2022/12. Nature cell biology, 24 (12) pp. 1689-1691. Peer-reviewed.
[DOI][Pmid][serval:BIB_A1B1B8C4A855]
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF494F840FDA]
 
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Lötscher J., Martí I Líndez A.A., Kirchhammer N., Cribioli E., Giordano Attianese GMP, Trefny M.P., Lenz M., Rothschild S.I., Strati P., Künzli M. et al., 2022/02/17. Cell, 185 (4) pp. 585-602.e29. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88810074314B]
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
Fierle J.K., Abram-Saliba J., Atsaves V., Brioschi M., de Tiani M., Reichenbach P., Irving M., Coukos G., Dunn S.M., 2022/01/21. Scientific reports, 12 (1) p. 1136. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D41964E1822]
 
A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
Irving M., Zoete V., Bassani-Sternberg M., Coukos G., 2022/01/10. Cancer cell, 40 (1) pp. 20-22. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FF0839215AF4]
 
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.
Cribioli E., Giordano Attianese GMP, Coukos G., Irving M., 2022. Frontiers in immunology, 13 p. 951143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BEC9380646B]
 
Enforcing GLUT3 expression in CD8+ T cells improves fitness and tumor control by promoting glucose uptake and energy storage
Cribioli E., Giordano Attianese GMP, Ginefra P., Signorino-Gelo A., Vuillefroy de Silly R., Vannini N., Hess C., Irving M., Coukos G., 2022. Frontiers in immunology, 13 p. 976628. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3101020C948F]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
Irving M., Lanitis E., Migliorini D., Ivics Z., Guedan S., 2021/10. Human gene therapy, 32 (19-20) pp. 1044-1058. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_24515EABFB7F]
 
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G. et al., 2021/08. Journal for immunotherapy of cancer, 9 (8) pp. e002151. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B098C62EF15]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
 
Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.
Merkle P.S., Trabjerg E., Hongjian S., Ferber M., Cuendet M.A., Jørgensen TJD, Luescher I., Irving M., Zoete V., Michielin O. et al., 2021/03/23. Biochemistry, 60 (11) pp. 859-872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF7649E47A67]
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig U.F., Majjigapu S.R., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P. et al., 2021/02/25. Journal of medicinal chemistry, 64 (4) pp. 2205-2227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FC8F8F2B6EC]
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Lanitis E., Rota G., Kosti P., Ronet C., Spill A., Seijo B., Romero P., Dangaj D., Coukos G., Irving M., 2021/02/01. The Journal of experimental medicine, 218 (2) pp. e20192203. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_75DE24FE756B]
2020
 
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.
Lanitis E., Coukos G., Irving M., 2020/10. Current opinion in biotechnology, 65 pp. 75-87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97CF39EFF89C]
High versus low dose irradiation for tumor immune reprogramming.
de Olza M.O., Bourhis J., Irving M., Coukos G., Herrera F.G., 2020/10. Current opinion in biotechnology, 65 pp. 268-283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_330632946BBD]
 
Correction to: Preclinical Evaluation and Dosimetry of [111In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)
Cicone Francesco, Denoël Thibaut, Gnesin Silvano, Riggi Nicolo, Irving Melita, Jakka Gopinadh, Schaefer Niklaus, Viertl David, Coukos George, Prior John O., 2020/08. 1.
[DOI][WoS][Pmid][serval:BIB_81A7D3CC3803]
Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1).
Cicone F., Denoël T., Gnesin S., Riggi N., Irving M., Jakka G., Schaefer N., Viertl D., Coukos G., Prior J.O., 2020/08. Molecular imaging and biology, 22 (4) pp. 979-991. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813B48F40C5F]
 
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G., Gainza P., Gray-Gaillard E., Cribioli E., Shui S., Kim S., Kwak M.J., Vollers S., Corria Osorio A.J., Reichenbach P. et al., 2020/04. Nature biotechnology, 38 (4) pp. 426-432. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EBAD72E3D84D]
miR-155 Overexpression in OT-1 CD8<sup>+</sup> T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.
Monnot G.C., Martinez-Usatorre A., Lanitis E., Lopes S.F., Cheng W.C., Ho P.C., Irving M., Coukos G., Donda A., Romero P., 2020/03/27. Molecular therapy oncolytics, 16 pp. 111-123. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_39DC24C5C585]
2019
 
CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8<sup>+</sup> T-cell Responses.
Liu Y., Cuendet M.A., Goffin L., Šachl R., Cebecauer M., Cariolato L., Guillaume P., Reichenbach P., Irving M., Coukos G. et al., 2019/12/06. Journal of molecular biology, 431 (24) pp. 4941-4958. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7D824F910BFC]
Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
Herrera F.G., Irving M., Kandalaft L.E., Coukos G., 2019/08. The Lancet. Oncology, 20 (8) pp. e417-e433. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B919A825548B]
 
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95C8776874F3]
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Wolf B., Zimmermann S., Arber C., Irving M., Trueb L., Coukos G., 2019/02. Drug safety, 42 (2) pp. 315-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_944ED4AF4291]
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S., Alatzoglou D., Irving M., Ménétrier-Caux C., Caux C., Romero P., Coukos G., 2019. Frontiers in immunology, 10 p. 925. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E661607B7DC8]
2018
Consensus guidelines for the use and interpretation of angiogenesis assays.
Nowak-Sliwinska P., Alitalo K., Allen E., Anisimov A., Aplin A.C., Auerbach R., Augustin H.G., Bates D.O., van Beijnum J.R., Bender RHF et al., 2018/08. Angiogenesis, 21 (3) pp. 425-532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0B60945B0B6F]
 
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y., Hu J., Wang Y., Peng X., Min J., Wang J., Matthaiou E., Cheng Y., Sun K., Tong X. et al., 2018/02. European journal of cancer, 90 pp. 111-121. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E091004637B]
Correction to: CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi B.O., Dumauthioz N., Marti B., Zhang L., Lanitis E., Irving M., Schneider P., Mach J.P., Coukos G., Romero P. et al., 2018. Journal for Immunotherapy of Cancer, 6 (1) p. 92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE20F9B96389]
2017
 
Mechanisms regulating T-cell infiltration and activity in solid tumors.
Lanitis E., Dangaj D., Irving M., Coukos G., 2017/12/01. Annals of oncology, 28 (suppl_12) pp. xii18-xii32. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE2398AAD635]
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
Irving M., Vuillefroy de Silly R., Scholten K., Dilek N., Coukos G., 2017. Frontiers in immunology, 8 p. 267. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E326B4204C76]
 
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.
Merkle P.S., Irving M., Hongjian S., Ferber M., Jørgensen TJD, Scholten K., Luescher I., Coukos G., Zoete V., Cuendet M.A. et al., 2017. Biochemistry, 56 (30) pp. 3945-3961. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7CF39E44F352]
2016
 
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
Röhrig U.F., Majjigapu S.R., Caldelari D., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P., Zoete V. et al., 2016/09/01. Bioorganic & medicinal chemistry letters, 26 (17) pp. 4330-4333. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9DF2682ECDFF]
 
In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI.
Gonzales C., Yoshihara H.A., Dilek N., Leignadier J., Irving M., Mieville P., Helm L., Michielin O., Schwitter J., 2016. PloS one, 11 (10) pp. e0164557. Peer-reviewed.
[DOI][Pmid][serval:BIB_1C2672B725FA]
2015
T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression.
Santoro S.P., Kim S., Motz G.T., Alatzoglou D., Li C., Irving M., Powell D.J., Coukos G., 2015. Cancer Immunology Research, 3 (1) pp. 68-84. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00550F80C313]
Targeting the tumor vasculature to enhance T cell activity.
Lanitis E., Irving M., Coukos G., 2015. Current Opinion in Immunology, 33 pp. 55-63. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_266C11B75B8F]
2013
 
Structure-Based, Rational Design of T Cell Receptors.
Zoete V., Irving M., Ferber M., Cuendet M.A., Michielin O., 2013. Frontiers in Immunology, 4 p. 268.
[DOI][WoS][Pmid][serval:BIB_CD515849E397]
2012
 
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
Irving M., Zoete V., Hebeisen M., Schmid D., Baumgartner P., Guillaume P., Romero P., Speiser D., Luescher I., Rufer N. et al., 2012. Journal of Biological Chemistry, 287 (27) pp. 23068-23078. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82B9FE6D3127]
2011
 
Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
Schmidt J., Guillaume P., Irving M., Baumgaertner P., Speiser D., Luescher I.F., 2011. Journal of Biological Chemistry, 286 (48) pp. 41723-41735.
[DOI][WoS][Pmid][serval:BIB_91E71143E739]
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires.
Leimgruber A., Ferber M., Irving M., Hussain-Kahn H., Wieckowski S., Derré L., Rufer N., Zoete V., Michielin O., 2011. PLoS One, 6 (10) pp. e26301.
[URN][DOI][WoS][Pmid][serval:BIB_A31DB21BDF3C]
2010
 
Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes
Irving Melita B., Craig Lisa, Menendez Alfredo, Gangadhar Beechanahalli P., Montero Marinieve, van Houten Nienke E., Scott Jamie K., 2010/02. Molecular Immunology, 47 (5) pp. 1137-1148.
[DOI][WoS][Pmid][serval:BIB_46A900E98AF3]
 
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
Schmid D.A., Irving M.B., Posevitz V., Hebeisen M., Posevitz-Fejfar A., Sarria J.C., Gomez-Eerland R., Thome M., Schumacher T.N., Romero P. et al., 2010. Journal of Immunology, 184 (9) pp. 4936-4946. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F3E1D237CD2]
2007
 
Structure of a High-affinity “Mimotope” Peptide Bound to HIV-1-neutralizing Antibody b12 Explains its Inability to Elicit gp120 Cross-reactive Antibodies
Saphire Erica Ollmann, Montero Marinieve, Menendez Alfredo, van Houten Nienke E., Irving Melita B., Pantophlet Ralph, Zwick Michael B., Parren Paul W.H.I., Burton Dennis R., Scott Jamie K. et al., 2007/06. Journal of Molecular Biology, 369 (3) pp. 696-709.
[DOI][WoS][Pmid][serval:BIB_5057CE658FDC]
2001
 
Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12
Zwick Michael B., Bonnycastle Lori L. C., Menendez Alfredo, Irving Melita B., Barbas Carlos F., Parren Paul W. H. I., Burton Dennis R., Scott Jamie K., 2001/07/15. Journal of Virology, 75 (14) pp. 6692-6699.
[DOI][WoS][Pmid][serval:BIB_6C4435ECFC2A]
 
Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics.
Irving M.B., Pan O., Scott J.K., 2001/06. Current opinion in chemical biology, 5 (3) pp. 314-324. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A155F2CEEF2C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University